Sarcoma最新文献

筛选
英文 中文
Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries. 评估类苔藓样纤维瘤病患者的心声:两个国家患者与健康相关的生活质量体验比较。
Sarcoma Pub Date : 2020-07-26 eCollection Date: 2020-01-01 DOI: 10.1155/2020/2141939
Milea J M Timbergen, Winette T A van der Graaf, Dirk J Grünhagen, Eugenie Younger, Stefan Sleijfer, Alison Dunlop, Lucy Dean, Cornelis Verhoef, Lonneke V van de Poll-Franse, Olga Husson
{"title":"Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries.","authors":"Milea J M Timbergen, Winette T A van der Graaf, Dirk J Grünhagen, Eugenie Younger, Stefan Sleijfer, Alison Dunlop, Lucy Dean, Cornelis Verhoef, Lonneke V van de Poll-Franse, Olga Husson","doi":"10.1155/2020/2141939","DOIUrl":"10.1155/2020/2141939","url":null,"abstract":"<p><strong>Purpose: </strong>Desmoid-type fibromatosis (DTF) is a rare, nonmetastasising soft tissue tumour. Symptoms, unpredictable growth, lack of definitive treatments, and the chronic character of the disease can significantly impact health-related quality of life (HRQoL). We aimed at identifying the most important HRQoL issues according to DTF patients in two countries, in order to devise a specific HRQoL questionnaire for this patient group.</p><p><strong>Methods: </strong>DTF patients and healthcare providers (HCPs) from the Netherlands and the United Kingdom individually ranked 124 issues regarding diagnosis, treatment, follow-up, recurrence, living with DTF, healthcare, and supportive care experiences, according to their relevance. Descriptive statistics were used to calculate priority scores.</p><p><strong>Results: </strong>The most highly ranked issues by patients (<i>n</i> = 29) were issues concerning \"tumour growth,\" \"feeling that there is something in the body that does not belong there,\" and \"fear of tumour growth into adjacent tissues or organs\" with mean (<i>M</i>) scores of 3.0, 2.9, and 2.8, respectively (Likert scale 1-4). British patients scored higher on most issues compared to Dutch patients (<i>M</i> 2.2 vs. <i>M</i> 1.5). HCPs (<i>n</i> = 31) gave higher scores on most issues compared to patients (<i>M</i> 2.3 vs. <i>M</i> 1.8).</p><p><strong>Conclusion: </strong>This study identified the most relevant issues for DTF patients, which should be included in a DTF-specific HRQoL questionnaire. Additionally, we identified differences in priority scores between British and Dutch participating patients. Field testing in a large, international cohort is needed to confirm these findings and to devise a comprehensive and specific HRQoL questionnaire for DTF patients.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"2141939"},"PeriodicalIF":0.0,"publicationDate":"2020-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38255735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Follow-Up in Bone Sarcoma Care: A Cross-Sectional European Study. 骨肉瘤治疗的随访:一项横断面欧洲研究。
Sarcoma Pub Date : 2020-06-30 eCollection Date: 2020-01-01 DOI: 10.1155/2020/2040347
Louren M Goedhart, Andreas Leithner, Joris J W Ploegmakers, Paul C Jutte
{"title":"Follow-Up in Bone Sarcoma Care: A Cross-Sectional European Study.","authors":"Louren M Goedhart,&nbsp;Andreas Leithner,&nbsp;Joris J W Ploegmakers,&nbsp;Paul C Jutte","doi":"10.1155/2020/2040347","DOIUrl":"https://doi.org/10.1155/2020/2040347","url":null,"abstract":"<p><strong>Background: </strong>Follow-up of high-grade bone sarcoma patients with repeated radiological imaging aims at early detection of recurrent disease or distant metastasis. Repeated radiological imaging does expose (mostly young) patients to ionising radiation. At this point, it is not known whether frequent follow-up increases overall survival. Additionally, frequent follow-up subjects patients and families to psychological stress. This study aims to assess follow-up procedures in terms of frequency and type of imaging modalities in bone tumour centres across Europe for comparison and improvement of knowledge as a first step towards a more uniform approach towards bone sarcoma follow-up.</p><p><strong>Methods: </strong>Data were obtained through analysis of several follow-up protocols and a digital questionnaire returned by EMSOS members of bone tumour centres all across Europe.</p><p><strong>Results: </strong>All participating bone tumour centres attained a minimum follow-up period of ten years. National guidelines revealed variations in follow-up intervals and use of repeated imaging with ionising radiation. A local and a chest X-ray were obtained at 47.6% of the responding clinics at every follow-up patient visit.</p><p><strong>Conclusions: </strong>Variations were seen among European bone sarcoma centres with regards to follow-up intervals and use of repeated imaging. The majority of these expert centres follow existing international guidelines and find them sufficient as basis for a follow-up surveillance programme despite lack of evidence. Future research should aim towards evidence-based follow-up with focus on the effects of follow-up strategies on health outcomes, cost-effectiveness, and individualised follow-up algorithms.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"2040347"},"PeriodicalIF":0.0,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2040347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38168682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Immunohistochemical Analysis of CD99 and PAX8 in a Series of 15 Molecularly Confirmed Cases of Ewing Sarcoma. 15例Ewing肉瘤分子确诊病例中CD99和PAX8的免疫组化分析
Sarcoma Pub Date : 2020-06-17 eCollection Date: 2020-01-01 DOI: 10.1155/2020/3180798
L M Chinchilla-Tábora, J Ortiz Rodríguez-Parets, I González Morais, J M Sayagués, M D Ludeña de la Cruz
{"title":"Immunohistochemical Analysis of CD99 and PAX8 in a Series of 15 Molecularly Confirmed Cases of Ewing Sarcoma.","authors":"L M Chinchilla-Tábora,&nbsp;J Ortiz Rodríguez-Parets,&nbsp;I González Morais,&nbsp;J M Sayagués,&nbsp;M D Ludeña de la Cruz","doi":"10.1155/2020/3180798","DOIUrl":"https://doi.org/10.1155/2020/3180798","url":null,"abstract":"<p><p>Ewing sarcomas are an uncommon group of malignant neoplasms. A multidisciplinary approach is highly recommended to reach a correct diagnosis, considering the clinical, radiological, and histopathological aspects. Since in up to 90% of cases, the translocation t (11; 22) (q24; q12) occurs resulting in a chimeric fusion transcript EWSR1-FLI-1. The pathologist has several tools in addition to conventional techniques (hematoxylin and eosin), such as immunohistochemistry, which plays a very important role in the differential diagnosis. We present a series of 15 cases of molecularly confirmed ES, in which we found a sensitivity of 100% for CD99 and 80% for PAX8 by immunohistochemistry. This indicates a high sensitivity; however, it is known that both CD99 and PAX8 are also expressed in other tumours. Therefore, molecular confirmation should be performed in all cases.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"3180798"},"PeriodicalIF":0.0,"publicationDate":"2020-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/3180798","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38168683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. PET/CT成像作为鉴别高分化与去分化脂肪肉瘤的诊断工具。
Sarcoma Pub Date : 2020-05-29 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8363986
Amanda Parkes, Elizabeth Urquiola, Priya Bhosale, Heather Lin, Kelsey Watson, Wei-Lien Wang, Barry Feig, Keila Torres, Christina L Roland, Anthony P Conley, Maria Zarzour, J Andrew Livingston, Ravin Ratan, Joseph Ludwig, Dejka M Araujo, Vinod Ravi, Robert S Benjamin, Shreyaskumar Patel, Neeta Somaiah
{"title":"PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma.","authors":"Amanda Parkes,&nbsp;Elizabeth Urquiola,&nbsp;Priya Bhosale,&nbsp;Heather Lin,&nbsp;Kelsey Watson,&nbsp;Wei-Lien Wang,&nbsp;Barry Feig,&nbsp;Keila Torres,&nbsp;Christina L Roland,&nbsp;Anthony P Conley,&nbsp;Maria Zarzour,&nbsp;J Andrew Livingston,&nbsp;Ravin Ratan,&nbsp;Joseph Ludwig,&nbsp;Dejka M Araujo,&nbsp;Vinod Ravi,&nbsp;Robert S Benjamin,&nbsp;Shreyaskumar Patel,&nbsp;Neeta Somaiah","doi":"10.1155/2020/8363986","DOIUrl":"https://doi.org/10.1155/2020/8363986","url":null,"abstract":"<p><p>Distinguishing well-differentiated liposarcoma (WDLPS) from dedifferentiated liposarcoma (DDLPS) is essential given distinct treatment paradigms and chemosensitivity. Percutaneous biopsy has a low sensitivity for detecting DDLPS. We sought to identify the diagnostic utility of positron emission tomography/computed tomography (PET/CT) in identifying WDLPS versus DDLPS. An independent radiologist reviewed PET/CT images to identify target lesions and determine the maximum standardized uptake value (SUVmax). An independent pathologist review confirmed WDLPS or DDLPS histology. A binary cutoff point of SUVmax was identified using a classification and regression trees (CART) algorithm. We identified 20 patients with WDLPS or DDLPS with 26 PET/CTs performed for separate recurrences that were followed by surgical sampling. Of the 26 records, 12 were DDLPS (46%) and 14 were WDLPS (54%). Patients with DDLPS had significantly higher SUVmax than those with WDLPS (<i>p</i> value = 0.0035). A SUVmax of 4 was identified as the cutoff point. Using this cutoff, the sensitivity of SUVmax identifying a case as DDLPS was 83.3% (95% CI: 51.6%, 97.9%) and the specificity was 85.7% (95% CI: 57.2%, 98.2%). PET/CT is a sensitive and specific diagnostic tool to identify the presence of dedifferentiation within the tumor.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"8363986"},"PeriodicalIF":0.0,"publicationDate":"2020-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8363986","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38069880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Time to Treatment Initiation and Survival in Adult Localized High-Grade Bone Sarcoma. 成人局部高级别骨肉瘤的开始治疗时间和生存率。
Sarcoma Pub Date : 2020-05-04 eCollection Date: 2020-01-01 DOI: 10.1155/2020/2984043
Joshua M Lawrenz, Joseph Featherall, Gannon L Curtis, Jaiben George, Yuxuan Jin, Peter M Anderson, Dale R Shepard, John D Reith, Brian P Rubin, Lukas M Nystrom, Nathan W Mesko
{"title":"Time to Treatment Initiation and Survival in Adult Localized High-Grade Bone Sarcoma.","authors":"Joshua M Lawrenz,&nbsp;Joseph Featherall,&nbsp;Gannon L Curtis,&nbsp;Jaiben George,&nbsp;Yuxuan Jin,&nbsp;Peter M Anderson,&nbsp;Dale R Shepard,&nbsp;John D Reith,&nbsp;Brian P Rubin,&nbsp;Lukas M Nystrom,&nbsp;Nathan W Mesko","doi":"10.1155/2020/2984043","DOIUrl":"https://doi.org/10.1155/2020/2984043","url":null,"abstract":"Objective Few studies have evaluated the prognostic implication of the length of time from diagnosis to treatment initiation in bone sarcoma. The purpose of this study is to determine if time to treatment initiation (TTI) influences overall survival in adults diagnosed with primary bone sarcoma. Methods A retrospective analysis of the National Cancer Database identified 2,122 patients who met inclusion criteria with localized, high-grade bone sarcoma diagnosed between 2004 and 2012. TTI was defined as length of time in days from diagnosis to initiation of treatment. Patient, disease-specific, and healthcare-related factors were also assessed for their association with overall survival. Kruskal-Wallis analysis was utilized for univariate analysis, and Cox regression modeling identified covariates associated with overall survival. Results Any 10-day increase in TTI was not associated with decreased overall survival (hazard ratio (HR) = 1.00; P=0.72). No differences in survival were detected at 1 year, 5 years, and 10 years, when comparing patients with TTI = 14, 30, 60, 90, and 150 days. Decreased survival was significantly associated (P < 0.05) with patient ages of 51–70 years (HR = 1.66; P=0.004) and > 71 years (HR = 2.89; P < 0.001), Charlson/Deyo score ≥2 (HR = 2.02; P < 0.001), pelvic tumor site (HR = 1.58; P < 0.001), tumor size >8 cm (HR = 1.52; P < 0.001), radiation (HR = 1.81; P < 0.001) as index treatment, and residing a distance of 51–100 miles from the treatment center (HR = 1.30; P=0.012). Increased survival was significantly associated (P < 0.05) with chordoma (HR = 0.27; P=0.010), chondrosarcoma (HR = 0.75; P=0.002), treatment at an academic center (HR = 0.64; P=0.039), and a private (HR = 0.67; P=0.006) or Medicare (HR = 0.71; P=0.043) insurer. A transition in care was not associated with a survival disadvantage (HR = 0.90; P=0.14). Conclusions Longer TTI was not associated with decreased overall survival in localized, high-grade primary bone sarcoma in adults. This is important in counseling patients, who may delay treatment to receive a second opinion or seek referral to a higher volume sarcoma center.","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"2984043"},"PeriodicalIF":0.0,"publicationDate":"2020-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2984043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37974776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma. 一种高风险未分化多形性肉瘤的深层功能和分子特征。
Sarcoma Pub Date : 2020-05-04 eCollection Date: 2020-01-01 DOI: 10.1155/2020/6312480
Noah E Berlow, Catherine S Grasso, Michael J Quist, Mingshan Cheng, Regina Gandour-Edwards, Brian S Hernandez, Joel E Michalek, Christopher Ryan, Paul Spellman, Ranadip Pal, Lynn S Million, Mark Renneker, Charles Keller
{"title":"Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma.","authors":"Noah E Berlow, Catherine S Grasso, Michael J Quist, Mingshan Cheng, Regina Gandour-Edwards, Brian S Hernandez, Joel E Michalek, Christopher Ryan, Paul Spellman, Ranadip Pal, Lynn S Million, Mark Renneker, Charles Keller","doi":"10.1155/2020/6312480","DOIUrl":"10.1155/2020/6312480","url":null,"abstract":"<p><p>Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft tissues of children, adolescents, and adults. Rarity of each subtype often precludes subtype-specific preclinical research, leaving many STS patients with limited treatment options should frontline therapy be insufficient. When clinical options are exhausted, personalized therapy assignment approaches may help direct patient care. Here, we report the results of an adult female STS patient with relapsed undifferentiated pleomorphic sarcoma (UPS) who self-drove exploration of a wide array of personalized Clinical Laboratory Improvement Amendments (CLIAs) level and research-level diagnostics, including state of the art genomic, proteomic, <i>ex vivo</i> live cell chemosensitivity testing, a patient-derived xenograft model, and immunoscoring. Her therapeutic choices were also diverse, including neoadjuvant chemotherapy, radiation therapy, and surgeries. Adjuvant and recurrence strategies included off-label and natural medicines, several immunotherapies, and N-of-1 approaches. Identified treatment options, especially those validated during the <i>in vivo</i> study, were not introduced into the course of clinical treatment but did provide plausible treatment regimens based on FDA-approved clinical agents.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"6312480"},"PeriodicalIF":0.0,"publicationDate":"2020-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38072895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. 一项随机、双盲、安慰剂对照、Saracatinib (AZD0530)治疗复发性肺骨肉瘤患者的2.5期研究结果
Sarcoma Pub Date : 2020-04-30 eCollection Date: 2020-01-01 DOI: 10.1155/2020/7935475
Kristin Baird, John Glod, Seth M Steinberg, Denise Reinke, Joseph G Pressey, Leo Mascarenhas, Noah Federman, Neyssa Marina, Sant Chawla, Joanne P Lagmay, John Goldberg, Mohammed Milhem, David M Loeb, James E Butrynski, Brian Turpin, Arthur Staddon, Sheri L Spunt, Robin L Jones, Eve T Rodler, Scott M Schuetze, Scott H Okuno, Lee Helman
{"title":"Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.","authors":"Kristin Baird,&nbsp;John Glod,&nbsp;Seth M Steinberg,&nbsp;Denise Reinke,&nbsp;Joseph G Pressey,&nbsp;Leo Mascarenhas,&nbsp;Noah Federman,&nbsp;Neyssa Marina,&nbsp;Sant Chawla,&nbsp;Joanne P Lagmay,&nbsp;John Goldberg,&nbsp;Mohammed Milhem,&nbsp;David M Loeb,&nbsp;James E Butrynski,&nbsp;Brian Turpin,&nbsp;Arthur Staddon,&nbsp;Sheri L Spunt,&nbsp;Robin L Jones,&nbsp;Eve T Rodler,&nbsp;Scott M Schuetze,&nbsp;Scott H Okuno,&nbsp;Lee Helman","doi":"10.1155/2020/7935475","DOIUrl":"https://doi.org/10.1155/2020/7935475","url":null,"abstract":"<p><strong>Purpose: </strong>Osteosarcoma is a rare cancer and a third of patients who have completed primary treatment will develop osteosarcoma recurrence. The Src pathway has been implicated in the metastatic behavior of osteosarcoma; about 95% of samples examined express Src or have evidence of downstream activation of this pathway. Saracatinib (AZD0530) is a potent and selective Src kinase inhibitor that was evaluated in adults in Phase 1 studies. The primary goal of this study was to determine if treatment with saracatinib could increase progression-free survival (PFS) for patients who have undergone complete resection of osteosarcoma lung metastases in a double-blinded, placebo-controlled trial. <i>Patients and Methods</i>. Subjects with recurrent osteosarcoma localized to lung and who had complete surgical removal of all lung nodules were randomized within six weeks after complete surgical resection. Saracatinib, or placebo, was administered at a dose of 175 mg orally, once daily, for up to thirteen 28-day cycles.</p><p><strong>Results: </strong>Thirty-seven subjects were included in the analyses; 18 subjects were randomized to receive saracatinib and 19 to receive placebo. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the saracatinib treatment group and 8.6 months in the placebo treatment group (<i>p</i>=0.47). Median OS was not reached in either arm.</p><p><strong>Conclusions: </strong>Although saracatinib was well tolerated in this patient population, there was no apparent impact of the drug in this double-blinded, placebo-controlled trial on OS, and Src inhibition alone may not be sufficient to suppress metastatic progression in osteosarcoma. There is a suggestion of potential clinical benefit as evidenced by longer PFS in patients randomized to saracatinib based on limited numbers of patients treated.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"7935475"},"PeriodicalIF":0.0,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/7935475","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37927184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. 骨肉瘤患者第二次复发后完全手术缓解期口服依托泊甙与白花蛇舌草作为维持疗法的随机研究的长期随访。
Sarcoma Pub Date : 2020-04-26 eCollection Date: 2020-01-01 DOI: 10.1155/2020/8260730
Alessandra Longhi, Marilena Cesari, Massimo Serra, Erminia Mariani
{"title":"Long-Term Follow-up of a Randomized Study of Oral Etoposide versus <i>Viscum album</i> Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse.","authors":"Alessandra Longhi, Marilena Cesari, Massimo Serra, Erminia Mariani","doi":"10.1155/2020/8260730","DOIUrl":"10.1155/2020/8260730","url":null,"abstract":"<p><strong>Background: </strong>In relapsed osteosarcoma, the 5-yr postrelapse disease-free survival (PRDFS) rate after the second relapse is <20%. In June 2007, a randomized study was started comparing oral etoposide vs <i>Viscum album</i> fermentatum Pini (an extract derived from the parasitic plant <i>Viscum album</i> L., European mistletoe) as maintenance therapy in patients with metastatic osteosarcoma in complete surgical remission after the second relapse. The primary endpoint was the PRDFS rate at 12 months (compared to the historical control rate). This is a long-term updated result. <i>Patients and Methods</i>. 10 patients received oral etoposide 50 mg/m<sup>2</sup> daily for 21 days every 28 days for 6 months, and 9 patients received <i>Viscum album</i> fermentatum Pini 3 times/wk subcutaneously for 1 year. The study closed early in July 2011 due to insufficient recruitment. Lymphocyte subpopulations were analyzed at T0, T3, T6, T9, and T12 months.</p><p><strong>Results: </strong>On 30 June 2019, at a median follow-up ITT of 83 months (range 3-144 ms), a median PRDFS of 106 ms (2-144) was observed in the <i>Viscum</i> arm with 5/9 patients who never relapse vs a PRDFS of 7 months (3-134) in the etoposide arm (all patients in the Etoposide arm relapsed) (hazard ratio HR = 0.287, 95% CI: 0.076-0.884, <i>p</i>=0.03). Model forecast 10-yr overall survival rates as 64% in the <i>Viscum</i> arm and 33% in the etoposide arm. Lymphocyte subpopulation counts (CD3, CD4, and CD56) showed an increase in the Viscum arm while a decrease was observed in the etoposide arm during treatment.</p><p><strong>Conclusions: </strong>After 12 years from the start of the trial, the patients in the <i>Viscum</i> arm continue to show a considerably longer PRDFS compared to oral etoposide, and a trend for an advantage in OS is evident even if the number of treated patients is too small to draw conclusions. <i>Viscum</i> as maintenance treatment after complete surgical remission in relapsed osteosarcoma should be further investigated and compared with other drugs.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"8260730"},"PeriodicalIF":0.0,"publicationDate":"2020-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37927185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current Approaches for Personalized Therapy of Soft Tissue Sarcomas. 软组织肉瘤个体化治疗的最新进展。
Sarcoma Pub Date : 2020-03-31 eCollection Date: 2020-01-01 DOI: 10.1155/2020/6716742
Kirill I Kirsanov, Ekaterina A Lesovaya, Timur I Fetisov, Beniamin Yu Bokhyan, Gennady A Belitsky, Marianna G Yakubovskaya
{"title":"Current Approaches for Personalized Therapy of Soft Tissue Sarcomas.","authors":"Kirill I Kirsanov,&nbsp;Ekaterina A Lesovaya,&nbsp;Timur I Fetisov,&nbsp;Beniamin Yu Bokhyan,&nbsp;Gennady A Belitsky,&nbsp;Marianna G Yakubovskaya","doi":"10.1155/2020/6716742","DOIUrl":"https://doi.org/10.1155/2020/6716742","url":null,"abstract":"<p><p>Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"6716742"},"PeriodicalIF":0.0,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6716742","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37857030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Clinical Outcomes of Osteoarticular Extracorporeal Irradiated Autograft for Malignant Bone Tumor. 自体骨关节体外辐照移植治疗恶性骨肿瘤的临床疗效。
Sarcoma Pub Date : 2020-03-30 eCollection Date: 2020-01-01 DOI: 10.1155/2020/9672093
Satoshi Takenaka, Nobuhito Araki, Takafumi Ueda, Shigeki Kakunaga, Yoshinori Imura, Ken-Ichiro Hamada, Hidetatsu Outani, Norifumi Naka, Akira Myoui, Hideki Yoshikawa
{"title":"Clinical Outcomes of Osteoarticular Extracorporeal Irradiated Autograft for Malignant Bone Tumor.","authors":"Satoshi Takenaka,&nbsp;Nobuhito Araki,&nbsp;Takafumi Ueda,&nbsp;Shigeki Kakunaga,&nbsp;Yoshinori Imura,&nbsp;Ken-Ichiro Hamada,&nbsp;Hidetatsu Outani,&nbsp;Norifumi Naka,&nbsp;Akira Myoui,&nbsp;Hideki Yoshikawa","doi":"10.1155/2020/9672093","DOIUrl":"https://doi.org/10.1155/2020/9672093","url":null,"abstract":"<p><strong>Methods: </strong>We retrospectively reviewed 33 patients who underwent osteoarticular ECIA after bone tumor resection from 1988 to 2014. We investigated complications, radiographic changes by the International Society of Limb Salvage graft evaluation criteria, and functional outcomes according to the Musculoskeletal Tumor Society scoring system.</p><p><strong>Results: </strong>Fifteen patients were reoperated upon due to infection (<i>n</i> = 9), protruding fixation implant (<i>n</i> = 4), or fracture of the grafted bone (<i>n</i> = 2). The average radiographic evaluation score was 66.4%, and the median functional score was 23 (77%). The radiographic score for the proximal humerus or proximal tibia was lower than that for the other locations. The functional score was not different among the autograft sites but was related to the radiographic score.</p><p><strong>Conclusion: </strong>Although osteoarticular ECIA is one of the reasonable surgical options for patients with tumors for which reliable prostheses are not available, we do not recommend osteoarticular ECIA as a routine procedure because of high complication rate.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"9672093"},"PeriodicalIF":0.0,"publicationDate":"2020-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9672093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37857061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信